These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 11289122)

  • 1. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
    Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
    Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases.
    Olopade OI; Adeyanju MO; Safa AR; Hagos F; Mick R; Thompson CB; Recant WM
    Cancer J Sci Am; 1997; 3(4):230-7. PubMed ID: 9263629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
    Aas T; Geisler S; Helle H; Børresen-Dale AL; Lønning PE; Akslen LA
    Oncol Rep; 2005 Mar; 13(3):525-30. PubMed ID: 15706428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
    Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
    Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
    Bièche I; Lidereau R
    Mol Carcinog; 2000 Nov; 29(3):151-8. PubMed ID: 11108660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
    Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
    Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
    Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.